Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)

This study has been terminated.
(The study is being terminated for lack of efficacy.)
Sponsor:
Collaborator:
Daiichi Sankyo Inc.
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01794000
First received: February 14, 2013
Last updated: June 15, 2016
Last verified: June 2016

February 14, 2013
June 15, 2016
April 2013
July 2015   (final data collection date for primary outcome measure)
Number of Vaso-Occlusive Crisis (VOC) Events Per Participant Per Year (Rate of VOC) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
The VOC is a composite endpoint of painful crisis or acute chest syndrome. Events that occurred within 7 days from the prior event onset date were not counted as a new episode. Data collected through the primary completion date reported below.
Number of Vaso-Occlusive Crisis (VOC) Events Per Participant Per Year (Rate of VOC) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01794000 on ClinicalTrials.gov Archive Site
  • Monthly Rate of Days With Pain [ Time Frame: Randomization through 9 Months ] [ Designated as safety issue: No ]
    Monthly rate of days with pain was measured through participant diaries using a modified version of the Faces Pain Scale-Revised (FPS-R). Each day participants selected the face on the scale that reflected their worst pain related to sickle cell disease (SCD) on that day. This pain scale contains six faces corresponding to the pain intensity of 0, 2, 4, 6, 8 or 10, in which 0 denotes no pain and 10 denotes the worst pain possible. Any day the participant selected a face other than face 0 was considered a day with pain. Monthly rate of days with pain was calculated for each participant by summing the number of days reported with any pain divided by the number of non-missing diary entries completed in the month. A month was defined as 4 weeks (28 days).The monthly rate was set to missing if there were more than 14 missing entries for the FPS-R in a specific month. Data collected through the primary completion date are present below.
  • Monthly Mean in Faces Pain Scale-Revised Score [ Time Frame: Randomization through 9 Months ] [ Designated as safety issue: No ]
    Each day participants selected the face on the FPS-R scale that reflected their worst pain related to sickle cell disease (SCD) on that day. Monthly mean in FPS-R score was calculated for each participant by summing the FPS-R score divided by the number of non-missing diary entries completed in the month. This pain scale contains six faces corresponding to the pain intensity of 0, 2, 4, 6, 8 or 10, in which 0 denotes no pain and 10 denotes the worst pain possible. A month was defined as 4 weeks (28 days). The monthly mean in FPS-R score was set to missing if there were more than 14 missing entries for the FPS-R in a specific month. Data collected through the primary completion date are presented below.
  • Number of Painful Crisis Events Per Participant Per Year (Rate of Painful Crisis) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
    A painful crisis is defined as an onset of moderate to severe pain that lasts at least 2 hours for which there is no explanation other than vaso-occlusion and which requires therapy with oral or parenteral opioids, ketorolac, or other analgesics prescribed by a health care provider (HCP) in a medical setting such as a hospital, clinic, emergency room visit, or telephone management. The painful crisis that occurred within 7 days from the prior event onset date was not counted as a new episode. Data collected through the primary completion date are presented below.
  • Number of Hospitalizations for VOC Per Participant Per Year (Rate of Hospitalizations) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
    Hospitalization that occurred within 7 days of the prior event onset date were not counted as a new episode. Data collected through the primary completion date are presented below.
  • Number of Acute Chest Syndrome Per Participant Per Year (Rate of Acute Chest Syndrome) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
    Acute chest syndrome was defined as an acute illness characterized by fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray. Acute chest syndrome that occurred within 7 days of the prior event onset date was not counted as a new episode. Data collected through the primary completion date are presented below.
  • Number of Red Blood Cell (RBC) Transfusions Due to Sickle Cell Disease (SCD) Per Participant Per Year (Rate of RBC Transfusions) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
    RBC transfusions that occurred within 7 days of the prior event onset date were not counted as a new episode. Data collected through the primary completion date are presented below.
  • Monthly Rate of Days of Analgesic Use [ Time Frame: Randomization through 9 Months ] [ Designated as safety issue: No ]
    Monthly rate of days of analgesic use was measured through participant diaries and was calculated for each participant by summing the number of days they reported analgesic use divided by the number of diary entries completed in the month. A month was defined as 4 weeks (28 days). The monthly rate was set to missing if there were more than 14 missing entries for analgesic use in a specific month. Data collected through the primary completion date are presented below.
  • Quarterly Rate of School Absence Due to Sickle Cell Pain [ Time Frame: Randomization through 9 Months ] [ Designated as safety issue: No ]
    Quarterly rate of school absence due to sickle cell pain was measured through participant diaries and was calculated for each participant by summing the number of days with school absence due to sickle cell pain divided by the number of school dates in the quarter. A quarter was defined as 12 weeks. The quarterly rate was set to missing if there were more than 6 weeks of missing diary entries during a specific quarter. Data collected through the primary completion date are presented below.
  • Time to First Transient Ischemic Attack (TIA)/Ischemic Stroke [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
  • Number of Days Hospitalized for VOC [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
    The total length of hospitalization in days for VOC was calculated for each participant. Data collected through the primary completion date are presented below.
  • Time From Randomization to First and Second VOC [ Time Frame: Randomization to First VOC and Second VOC respectively (up to 24 Months) ] [ Designated as safety issue: No ]
    Data collected through the primary completion date are presented below.
  • Percentage of Participants With Hemorrhagic Events Requiring Medical Intervention [ Time Frame: First Dose through 24 Months ] [ Designated as safety issue: Yes ]
    Medical intervention was defined as any medical evaluation resulting in therapy or further investigation, as determined by a trained medical professional. Data collected from the first dose of study medication through 10 days after last dose of study medication during the double blind study period are presented below.
  • Monthly Rate of Days With Pain [ Time Frame: Randomization through 9 Months ] [ Designated as safety issue: No ]
  • Monthly Mean in Faces Pain Scale-Revised Score [ Time Frame: Randomization through 9 Months ] [ Designated as safety issue: No ]
  • Number of Hospitalizations for VOC Per Participant Per Year (Rate of Hospitalizations) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
  • Number of Acute Chest Syndrome Per Participant Per Year (Rate of Acute Chest Syndrome) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
  • Number of Red Blood Cell (RBC) Transfusions due to SCD per Participant per Year (Rate of RBC Infusions) [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
  • Monthly Rate of Days of Analgesic Use [ Time Frame: Randomization through 9 Months ] [ Designated as safety issue: No ]
  • Quarterly Rate of School Absence Due to Sickle Cell Pain [ Time Frame: Randomization through 9 Months ] [ Designated as safety issue: No ]
  • Percentage of Participants with Transient Ischemic Attack (TIA)/Ischemic Stroke [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
  • Number of Days Hospitalized for VOC [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: No ]
  • Time From Randomization to First and Second VOC [ Time Frame: Randomization to First and Second VOC (Estimated up to 24 Months) ] [ Designated as safety issue: No ]
  • Percentage of Participants With Hemorrhagic Events Requiring Medical Intervention [ Time Frame: Randomization through 24 Months ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.
The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease. The study will also investigate reduction in daily pain in children who have sickle cell disease.

The submission database was validated for data reported through the data cutoff date for the submission database lock (SDBL). The SDBL data cutoff was 17 July 2015 for all participants except for 2 in the youngest age group, for whom the SDBL data cutoff occurred on 08 August 2015. The data cutoff date for SDBL corresponds to the primary completion date for the study. The SDBL occurred on 31 August 2015.

The study was stopped following SDBL and review of the topline information indicated that the primary and secondary efficacy endpoints were not met. Subsequently, the Sponsor requested that participants discontinue study drug immediately and that discontinuation visits for all active study participants be conducted as soon as feasible.

After the data cutoff date for SDBL, the Sponsor continued to collect safety data through the final participants contact; some additional efficacy data were collected through the final visit. The last patient visit (LPV) occurred on 17 December 2015, which corresponds to the study completion date and led to the planned supplemental database lock (PSDBL) on 22 January 2016. This supplemental data base was originally designed to capture additional blinded and randomized information to enhance safety data for labeling should the study have been positive.

The safety information contained in this record reflects the entire safety information and reflects the information from the supplemental data base lock in January of 2016. The efficacy information contained in this record reflects the information collected through primary completion date in the submission database. Primary analyses of the major efficacy objectives were repeated using the entire double-blind period data from the PSDBL and did not change the original conclusions and were consistent with the results from the original efficacy analyses included in the SDBL.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Sickle Cell Disease
  • Drug: Prasugrel
    Administered orally
    Other Names:
    • LY640315
    • Effient
    • Efient
  • Drug: Placebo
    Administered orally
  • Experimental: Prasugrel
    Participants will be titrated from initial daily dose of 0.08 milligram per kilogram (mg/kg) of orally administered prasugrel monotherapy at randomization to a dose that will achieve a P2Y12 reaction units (PRU) level of 231 to 136, as measured by VerifyNow instrument. This corresponds to a range of platelet inhibition of approximately 30% to 60%. The maximum possible dose allowed is 0.12 mg/kg daily, not to exceed 10 mg daily.
    Intervention: Drug: Prasugrel
  • Placebo Comparator: Placebo
    Participants in this treatment group will receive daily orally administered placebo and will follow visit schedule identical to that in the active treatment group.
    Intervention: Drug: Placebo
Heeney MM, Hoppe CC, Abboud MR, Inusa B, Kanter J, Ogutu B, Brown PB, Heath LE, Jakubowski JA, Zhou C, Zamoryakhin D, Agbenyega T, Colombatti R, Hassab HM, Nduba VN, Oyieko JN, Robitaille N, Segbefia CI, Rees DC; DOVE Investigators.. A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
341
December 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have SCD [homozygous sickle cell (HbSS) or hemoglobin (HbS) Beta^0 thalassemia]
  • Are participants with SCD who have had ≥2 episodes of vaso-occlusive crisis (VOC) in the past year
  • Have a body weight ≥19 kilograms (kg) and are ≥2 and <18 years of age, inclusive at the time of screening
  • If participants are ≥2 and ≤16 years of age, must have had a transcranial Doppler within the last year

Exclusion Criteria:

  • History of: transient ischemic attack (TIA)/ ischemic or hemorrhagic stroke, severe head trauma, intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm
  • History of abnormal or conditional [velocity in middle or anterior cerebral, or internal carotid artery ≥170 centimeter per second (cm/sec)] transcranial Doppler within the last year
  • History of, or are undergoing treatment with, chronic red blood cell (RBC) transfusion therapy
  • Are at an increased risk for bleeding complications
  • Are receiving chronic treatment with nonsteroidal anti-inflammatory drug (NSAID)s and cannot be switched to another analgesic
Both
2 Years to 17 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States,   Belgium,   Brazil,   Canada,   Egypt,   Ghana,   Italy,   Kenya,   Lebanon,   Oman,   Saudi Arabia,   Turkey,   United Arab Emirates,   United Kingdom
France,   Netherlands
 
NCT01794000
13038, H7T-MC-TADO, 2012-003837-41
Yes
Yes

Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.

This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.

Eli Lilly and Company
Eli Lilly and Company
Daiichi Sankyo Inc.
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP